Effect of tolvaptan in decompensated liver cirrhosis patients

Effect of tolvaptan in decompensated liver cirrhosis patients - Effect of tolvaptan inliver cirrhosis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016188

Enrollment

Registered

2015-01-12

Start date

2014-12-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensated liver cirrhosis patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This trial enrolled decompensated liver cirrhosis patients with ascites despite undergoing combination therapy with a loop diuretic unless the subject is intolerant of diuretics

Exclusion criteria

Exclusion criteria: (1)The anuric patients (2)Patients with urinary retention (3) hypernatremia (4)Patients with poorly controlled hepatocellular carcinoma and hepatic encephalopathy were exclude

Design outcomes

Primary

Measure	Time frame
Mean differences between daily urine volume and body weight after administration of tolvaptan	—

Countries

Japan

Contacts

Public Contactuojima haruki

shonan kamakura general hospital department of gastroenterology

kiruha555@yahoo.co.jp0467-46-1717

Outcome results